Geron Corporation Appoints Ying Wan as Vice President, Biometrics and Patrick Murphy as Vice President, Manufacturing
May 16, 2019 at 06:00 am EDT
Share
Geron Corporation announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing. Their oncology and drug development expertise will support Geron’s late-stage clinical development, including the planned opening of the Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes for screening and enrollment by mid-year 2019. The company appointed Ying Wan as Vice President, Biometrics. Prior to Geron, Dr. Wan was Director and Functional Leader, Oncology Statistics, Statistics & Decision Sciences at Janssen Research and Development, LLC. As Vice President, Biometrics, Dr. Wan will manage and lead biostatistics and statistical programming. This includes leading statistical strategy for clinical development; supporting clinical projects by implementing innovative approaches in designs and analyses plans; and providing statistical and programming deliverables for clinical programs and submissions, while ensuring compliance with regulatory guidance, standards and processes. The company appointed Patrick Murphy as Vice President, Manufacturing. Prior to joining Geron, Mr. Murphy was Vice President, Technical Operations at Omniox Inc. As Vice President, Manufacturing, Mr. Murphy will lead the manufacturing function, which includes developing and executing a comprehensive global CMC strategy that encompasses manufacturing, process development, supply chain management, and technology transfer, across the product lifecycle of imetelstat from the planned Phase 3 clinical trial in lower risk myelodysplastic syndromes to potential new drug applications, and preparing for commercial manufacturing.
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.